Monoclonal antibody serial passage escape
- Most but stiil only mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody.
Most and moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody (Greaney et al. (2020))
- Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab) (Starr et al. (2021))
Automatically generated using text2ui script and data from Pokay